Ruben Blachman-Braun, MD, MSc is a board-eligible urologist and Urologic Oncology Fellow at the National Cancer Institute, NIH. He specializes in the surgical and clinical management of urological cancers, including prostate, kidney, and bladder cancer, with expertise in robotic, laparoscopic, and focal therapies such as TULSA, HIFU, and laser ablation. Dr. Blachman-Braun earned his MD and MSc from Anahuac University in Mexico and completed his urology residency at the University of Miami / Jackson Memorial Hospital.
An accomplished researcher, he has authored over 125 peer-reviewed publications, edited several medical books, and presented his work at numerous national and international conferences. His research focuses on hereditary cancer syndromes, surgical outcomes, molecular genetics, and the integration of innovative technologies in cancer care.
He serves as Associate Editor of Frontiers in Urology, has reviewed for top journals including Urologic Oncology, European Urology Focus, and JAMA, and is an active member of the American Urological Association, the Endourological Society, and the Focal Therapy Society. Dr. Blachman-Braun’s career bridges surgery, genetics, and translational research, with a strong commitment to innovation, multidisciplinary collaboration, and improving patient outcomes in urologic oncology.
Ruben Blachman-Braun, MD, MSc is a board-eligible urologist and Urologic Oncology Fellow at the National Cancer Institute, NIH. He specializes in the surgical and clinical management of urological cancers, including prostate, kidney, and bladder cancer, with expertise in robotic, laparoscopic, and focal therapies such as TULSA, HIFU, and laser ablation. Dr. Blachman-Braun earned his MD and MSc from Anahuac University in Mexico and completed his urology residency at the University of Miami / Jackson Memorial Hospital.
An accomplished researcher, he has authored over 125 peer-reviewed publications, edited several medical books, and presented his work at numerous national and international conferences. His research focuses on hereditary cancer syndromes, surgical outcomes, molecular genetics, and the integration of innovative technologies in cancer care.
He serves as Associate Editor of Frontiers in Urology, has reviewed for top journals including Urologic Oncology, European Urology Focus, and JAMA, and is an active member of the American Urological Association, the Endourological Society, and the Focal Therapy Society. Dr. Blachman-Braun’s career bridges surgery, genetics, and translational research, with a strong commitment to innovation, multidisciplinary collaboration, and improving patient outcomes in urologic oncology.